Get started
Author

Laure Cosson

Observed names: L. Cosson, Laure COSSON
Observed institutions: Université de Tours, Centre Hospitalier Universitaire de Nantes, Centre Hospitalier Universitaire de Besançon, Centre Hospitalier Universitaire de Tours, Institut du Thorax, Nantes Université
ORCID: 0000-0001-9469-9796
Observed ORCID: 0000-0001-9469-9796
OpenAlex ID: A5021833257
Theratyping cystic fibrosis patients to guide elexacaftor/tezacaftor/ivacaftor out-of-label prescription
2023 · Elise Dreano, Pierre Régis Burgel, et al. · European Respiratory Journal · 97
The expanded French compassionate programme for elexacaftor–tezacaftor–ivacaftor use in people with cystic fibrosis without a F508del CFTR variant: a real-world study
2024 · Pierre-Régis Burgel, Isabelle Sermet-Gaudelus, et al. · The Lancet Respiratory Medicine · 68
PDF
Effect of one-year lumacaftor–ivacaftor treatment on glucose tolerance abnormalities in cystic fibrosis patients
2020 · Bastien Misgault, Eva Chatron, et al. · Journal of Cystic Fibrosis · 65
PDF
Barth syndrome in a female patient
2012 · Laure Cosson, Annick Toutain, et al. · Molecular Genetics and Metabolism · 63
Behavioural and sleep issues after initiation of elexacaftor–tezacaftor–ivacaftor in preschool-age children with cystic fibrosis
2024 · I Sermet-Gaudelus, Sihem Benaboud, et al. · The Lancet · 29
PDF
Advent of elexacaftor/tezacaftor/ivacaftor for cystic fibrosis treatment: What consequences on Aspergillus-related diseases? Preliminary insights
2022 · Adélaïde Chesnay, Éric Bailly, et al. · Journal of Cystic Fibrosis · 20
Sweat chloride and lung function responses to elexacaftor–tezacaftor–ivacaftor in people with cystic fibrosis with two versus one responsive CFTR variants: an analysis of two real-world observational studies
2025 · Pierre-Régis Burgel, Jennifer Da Silva, et al. · The Lancet Respiratory Medicine · 18
Cumulative Incidence and Risk Factors for Severe Coronavirus Disease 2019 in French People With Cystic Fibrosis
2022 · Harriet Corvol, Sandra de Miranda, et al. · Clinical Infectious Diseases · 17
PDF
Reclassifying inconclusive diagnosis for cystic fibrosis with new generation sweat test
2022 · Thao Nguyen-Khoa, Aurélie Hatton, et al. · European Respiratory Journal · 14
Real-World Long-Term Ivacaftor for Cystic Fibrosis in France: Clinical Effectiveness and Healthcare Resource Utilization
2021 · Dominique Hubert, Christophe Marguet, et al. · Pulmonary Therapy · 13
PDF
Beyond Trikafta: new models to assess tissue dependent rescue of N1303K-CFTR
2025 · Iwona Pranke, Valeria Capurro, et al. · Frontiers in Pharmacology · 10
PDF
Effect of Elexacaftor/Tezacaftor/Ivacaftor on Glucose Tolerance in Adolescents With Cystic Fibrosis
2025 · Alfonso Galderisi, Laurence Weiss, et al. · The Journal of Clinical Endocrinology & Metabolism · 9
D e novo SRRM2 variants in neuroendocrine cell hyperplasia of infancy and persistent tachypnoea of infancy
2025 · Camille Louvrier, Yohan Soreze, et al. · European Respiratory Journal · 7
Le syndrome de Donohue ou lepréchaunisme : à propos d’un cas
2014 · D. Planchenault, D. Martin-Coignard, et al. · Archives de Pédiatrie · 7
Seasonal and climatic influence on respiratory infections in children with cystic fibrosis
2024 · Julie Mésinèle, Manon Ruffin, et al. · Scientific Reports · 2
PDF
Beyond Kaftrio : mechanistic insights to maximize N1303K-CFTR rescue
2024 · Iwona Pranke, Valeria Capurro, et al. · bioRxiv (Cold Spring Harbor Laboratory) · 2
PDF
Outcomes of SARS-CoV-2 infection post-solid organ transplantation in the cystic fibrosis population
2026 · Julie Semenchuk, Yumi Naito, et al. · Journal of Cystic Fibrosis · 1
PDF
Impact of Elexacaftor-Tezacaftor-Ivacaftor on fungal colonisation in children and adolescents with cystic fibrosis
2026 · Emilie Sitterlé, Anne-Sophie Bonnel, et al. · Journal of Cystic Fibrosis · 1
Continuous glucose monitoring to track metabolic changes in youths with cystic fibrosis before and after initiation of elexacaftor/tezacaftor/ivacaftor therapy
2026 · Alfonso Galderisi, Hadija Marchiori, et al. · The Journal of Clinical Endocrinology & Metabolism
Adherence patterns and their determinants to CFTR modulators in France
2026 · Oriane Talabart, Elia Eid, et al. · Respiratory Medicine
PDF
Early Years Matter: Effects of Elexacaftor-Tezacaftor-Ivacaftor on Cystic Fibrosis Disease Progression in Children 2 through 5 Years
2026 · Isabelle Sermet, Alexia Letierce, et al. · SSRN Electronic Journal
689 Triple CFTR modulator combination improves glucose tolerance in adolescents with cystic fibrosis: data from the French observational pediatric study MODUL-CF
2024 · L. Weiss, A. Galderisi, et al. · Journal of Cystic Fibrosis
P286 Triple CFTR modulator combination improves glucose tolerance in adolescents with cystic fibrosis. Data from the French observational paediatric study MODUL-CF
2024 · L. Weiss, A. Galderisi, et al. · Journal of Cystic Fibrosis
Pulmonary mucoepidermoid carcinoma in a 7‐year‐old child
2024 · Sophie Denamur, Erik Hervieux, et al. · Pediatric Pulmonology
Correction to: Real-World Long-Term Ivacaftor for Cystic Fibrosis in France: Clinical Effectiveness and Healthcare Resource Utilization
2021 · Dominique Hubert, Christophe Marguet, et al. · Pulmonary Therapy
PDF
Works count: 26
Citation count: 461
H-index: 11
I10-index: 12
Year
Topic
Type